Oral corticosteroids remain the cornerstone therapy for sarcoidosis. C
ritical clinical decisions include selecting the patient who should be
treated, dose and duration of therapy, and accurate analysis of the a
nticipated benefits and potential side effects for the individual pati
ent. The treatment of pulmonary and cardiac sarcoidosis is emphasized
and the role of inhaled corticosteroids in the treatment of pulmonary
sarcoidosis is reviewed.